Breaking Down 6 Late-stage NASH Drugs Poised to Compete with REZDIFFRA

 

The Race for the Next Best NASH Drug

Nonalcoholic Steatohepatitis (NASH) is a chronic liver disease with no FDA-approved treatments until recently, when Rezdiffra emerged as a frontrunner in NASH treatment. However, with a rising number of cases globally, the competition to dominate the NASH market is fierce. Numerous late-stage drugs in the NASH pipeline are challenging Rezdiffra's market dominance, each aiming to address the unmet medical needs of patients.


1. Resmetirom: Developed by Madrigal Pharmaceuticals, this thyroid hormone receptor-β agonist has shown potential to reduce liver fat, inflammation, and fibrosis in late-stage clinical trials. Resmetirom could significantly impact the NASH market size.


2. Lanifibranor: A pan-PPAR agonist developed by Inventiva, Lanifibranor is another promising candidate, currently in Phase III trials. It has demonstrated efficacy in reducing fibrosis and liver injury, making it a competitor to Rezdiffra in the Nonalcoholic Steatohepatitis treatment landscape.


3. Obeticholic Acid (OCA): Intercept Pharmaceuticals' OCA is a farnesoid X receptor (FXR) agonist that has progressed in clinical trials, focusing on reducing liver fibrosis in NASH patients. It’s well-positioned to enter the NASH market as a strong contender.


4. Cenicriviroc: Cenicriviroc, a dual CCR2/CCR5 antagonist developed by Allergan, is under investigation for its anti-inflammatory and anti-fibrotic properties, potentially offering an alternative NASH treatment option.


5. Semaglutide: Novo Nordisk’s GLP-1 receptor agonist, known for its efficacy in diabetes and obesity, is being repurposed for NASH. It has shown promise in reducing liver inflammation and fat.


6. Aldafermin: Developed by NGM Biopharmaceuticals, this engineered variant of FGF19 aims to reduce liver fat content and fibrosis, posing a direct challenge to Rezdiffra’s hold on the NASH market.

Conclusion:

While Rezdiffra currently leads the Nonalcoholic Steatohepatitis treatment space, these six NASH drugs are quickly advancing through clinical trials. With increasing investments in the NASH pipeline, the competition to dominate the market is heating up, potentially reshaping the future of NASH treatments in the coming years.

Latest Reports Offered By DelveInsight:

Preeclampsia Market | Emphysema Market | Fetal Monitoring Devices Market | Hemostasis Market | Urinary Tract Infection Devices Market | Acute Lymphoblastic Leukemia Market Market | Artificial Cornea And Corneal Implan Market | Dental Laser Market | Mrna Vaccines & Therapeutics Market | Acute Lymphocytic Leukemia Market | Mrna Based Vaccines And Therapeutics Market | Deep Brain Stimulation Market | Structural Heart Devices Market | Global Kinase Inhibitor Market | Prosthetic Heart Valve Market | India Healthcare Report | Ventilator Market | Trastuzuma Biosimilar

Comments

Post a Comment

Popular posts from this blog

The Great PD-1 Inhibitor Battle: OPDIVO vs. KEYTRUDA in Japan

Image
  Analyzing OPDIVO’s Pre-2022 Sales Decline and KEYTRUDA’s Market Ascendancy Before 2022, OPDIVO, developed by Bristol-Myers Squibb (BMS), faced a significant sales decline in Japan’s PD-1 inhibitor market. Despite its initial success, the PD-1 and PD-L1 inhibitors faced challenges from new competitors and evolving market dynamics. One key competitor was Merck's KEYTRUDA, which steadily gained market share due to its broader range of approved indications and successful clinical trial outcomes. KEYTRUDA’s market ascendancy was marked by its approval for various cancers, including melanoma, non-small cell lung cancer, and urothelial carcinoma, among others, making it a versatile choice for oncologists. How OPDIVO Outpaced KEYTRUDA in Japan’s Pharmaceutical Market In 2022, OPDIVO made a remarkable comeback, outpacing KEYTRUDA in Japan’s pharmaceutical market. This resurgence was driven by several strategic moves by BMS. The company expanded OPDIVO’s indications, securing approvals fo
Read more

A detailed analysis of Vascular Stents Market Trends, Growth Opportunities, Challenges, and Epidemiology Forecast

Image
A vascular surgeon places a stent, which is a hollow mesh tube that supports the blood vessel's walls permanently and prevents it from closing up again (restenosis). Some stents are drug-eluting, which means they release medicine over time to help prevent another blockage. The  Vascular Stents market is being driven by a growing geriatric population as well as an increase in the number of surgical operations. The  Vascular Stents Market report from DelveInsight provides an in-depth analysis of  Vascular Stents, as well as historical and forecasted market trends in the 7MM (the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Some Key Highlights from the  Vascular Stents Market Report The artery is kept open by a stent, which is a small metal mesh tube. The two methods for opening clogged peripheral arteries are angioplasty and stent implantation. Vascular Stents market is segmented on the basis of Product type, By Applications and End-user. Some of the
Read more
Image
Obstructive Sleep Apnea Market Trends and Therapeutic Advancements !! Obstructive Sleep Apnea (OSA) is a common chronic sleep disorder, which is characterized by periodic narrowing and obstruction of the pharyngeal airway during sleep, leading to a complete or partial obstruction of the airway, results of which are apneas, hypopneas, or sometimes both. Obstructive sleep apnea is a chronic and permanent condition, through proper therapy and medications the condition can be cured. Almost every system in the body is affected by Obstructive Sleep Apnea, resulting in an increased incidence of hypertension, stroke, altered immune system, and cardiovascular disease.  Obstructive Sleep Apnea is caused when the throat muscles relax during sleep, which causes the tissue in the back of the throat to collapse and block the upper airway. Daytime sleepiness is one of the most common symptoms of Obstructive Sleep Apnea. People affected with Obstructive Apnea also complain of memory problems, headach
Read more